Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Heart ; 110(12): 823-830, 2024 May 23.
Artigo em Inglês | MEDLINE | ID: mdl-38267197

RESUMO

The prevalence of amyloidosis has been increasing, driven by a combination of improved awareness, evolution of diagnostic pathways, and effective treatment options for both transthyretin and light chain amyloidosis. Due to the complexity of amyloidosis, centralised expert providers with experience in delineating the nuances of confirmatory diagnosis and management may be beneficial. There are many potential benefits of a centre of excellence designation for the treatment of amyloidosis including recognition of institutions that have been leading the way for the optimal treatment of this condition, establishing the expectations for any centre who is engaging in the treatment of amyloidosis and developing cooperative groups to allow more effective research in this disease space. Standardising the expectations and criteria for these centres is essential for ensuring the highest quality of clinical care and community education. In order to define what components are necessary for an effective centre of excellence for the treatment of amyloidosis, we prepared a survey in cooperation with a multidisciplinary panel of amyloidosis experts representing an international consortium. The purpose of this position statement is to identify the essential elements necessary for highly effective clinical care and to develop a general standard with which practices or institutions could be recognised as a centre of excellence.


Assuntos
Amiloidose , Humanos , Amiloidose/terapia , Amiloidose/diagnóstico , Cardiomiopatias/terapia , Cardiomiopatias/diagnóstico , Cardiologia/normas , Sociedades Médicas , Oncologia/normas , Cardio-Oncologia
2.
BMJ Support Palliat Care ; 10(4): 404-410, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-32943468

RESUMO

Exercise is a well-established factor which improves outcomes of oncological patients during curative treatment as well as in cancer survivors. However, the role of physical activity in metastatic disease, due to the deficiency of high-level evidence from prospective clinical trials, remains a partially unexplored field of research. Additionally, no specific guidelines related to exercise for persons with advanced cancer have been developed so far. Unfortunately, this research deficit may effectively prevent physicians from prescribing adequate and safe recommendations on physical activity to their patients. In an attempt to fill this gap in clinical practice, we present here an up-to-date review of potential benefits of exercise interventions in relation to the survival, quality of life and supportive care for patients with metastatic cancer. We also review the data on the safety of physical activity with special emphasis on elderly populations or individuals with bone metastases. Finally, we discuss the most relevant clinical factors that should be considered during exercise qualification. In conclusion, physical activity is an important tool for improving the outcomes of people undergoing anticancer therapy for metastatic disease. However, the training should be tailored individually to the patient's functional status, comorbidities and preferences. Physical activity should become a standard component of every metastatic cancer care plan.


Assuntos
Terapia por Exercício/métodos , Metástase Neoplásica/terapia , Sobreviventes de Câncer , Gerenciamento Clínico , Terapia por Exercício/tendências , Humanos
3.
J Cardiovasc Transl Res ; 13(3): 495-505, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32444945

RESUMO

The burgeoning field of cardio-oncology (C-O) is now necessary for the delivery of excellent care for patients with cancer. Many factors have contributed to this increasing population of cancer survivors or those being treated with novel and targeted cancer therapies. There is a tremendous need to provide outstanding cardiovascular (CV) care for these patients; however, current medical literature actually provides a paucity of guidance. C-O therefore provides a novel opportunity for clinical, translational, and basic research to advance patient care. This review aims to be a primer for cardio-oncologists on how to develop a vibrant and comprehensive C-O program, use practical tools to assist in the construction of C-O services, and to proactively incorporate translational and clinical research into the training of future leaders as well as enhance clinical care.


Assuntos
Antineoplásicos/efeitos adversos , Sobreviventes de Câncer , Cardiologia/organização & administração , Assistência Integral à Saúde/organização & administração , Prestação Integrada de Cuidados de Saúde/organização & administração , Cardiopatias/diagnóstico por imagem , Oncologia/organização & administração , Neoplasias/tratamento farmacológico , Técnicas de Imagem Cardíaca , Cardiotoxicidade , Cardiopatias/induzido quimicamente , Humanos , Valor Preditivo dos Testes , Prognóstico , Indicadores de Qualidade em Assistência à Saúde/organização & administração , Medição de Risco , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa